ROS1 and non-small cell lung carcinoma: It would also be interesting to ask whether the association of thrombosis/anticoagulation with worse outcome is unique to ROS1‐ and ALK‐rearranged NSCLCs by conducting similar analyses in other molecularly defined subtypes of NSCLC treated with relevant targeted therapies.